The US Sustained Release Coatings Market was valued at USD 276.4 million in 2025 and is projected to reach USD 689.7 million by 2035, expanding at a CAGR of 8.7% during the forecast period 2024 to 2035. This market growth is primarily driven by rising demand in pharmaceuticals for enhanced drug delivery, and the increasing prevalence of chronic diseases requiring sustained therapeutics.
The economic impact of tariffs on "US Sustained Release Coatings Market".
Market Growth Drivers
Increased Demand for Advanced Drug Delivery: The US pharmaceutical sector is seeing a surging demand for innovative drug delivery systems, particularly those that improve patient compliance and therapeutic outcomes. Sustained release coatings allow for the timed release of active pharmaceutical ingredients, reducing dosing frequency and enhancing treatment adherence. Companies like Colorcon Inc. have expanded their portfolio to offer functional coatings that cater to complex drug formulations, partnering with major pharma firms for customized solutions.
Growing Prevalence of Chronic Diseases: The rise in chronic health conditions such as diabetes, cardiovascular disorders, and CNS diseases has spurred demand for long-acting medications. As a result, the need for sustained release tablets and capsules has increased, propelling the market for high-quality coating materials. Evonik Industries has recently reported increased orders from contract development and manufacturing organizations (CDMOs) aiming to formulate extended-release oral dosage forms.
Market Trends
Shift Towards Natural and Biodegradable Coating Materials: Leading manufacturers are innovating with plant-based and biodegradable polymers for sustained release coatings, addressing environmental concerns and regulatory pressures. Companies like Ashland Global Holdings are investing in research and commercialization of cellulose derivatives that not only meet performance criteria but also support green chemistry and sustainability objectives.
Adoption of Continuous Manufacturing Technologies: The pharmaceutical industry in the US is increasingly implementing continuous manufacturing processes to improve efficiency and product quality. This technological trend requires compatible sustained release coating formulations that can be precisely applied and controlled in real-time. Catalent, for instance, has incorporated advanced coating systems suited for continuous processing, optimizing batch-to-batch consistency and regulatory compliance.
Market Opportunity
Expansion into Nutraceuticals: As consumer demand for supplements with controlled nutrient delivery rises, there is a significant opportunity for companies like BASF to diversify sustained release coating applications in the nutraceutical sector, ensuring prolonged efficacy and consumer safety.
Personalized Medicine Initiatives: The growth of precision therapeutics creates room for tailored sustained release coating solutions, enabling firms such as Lonza Group to collaborate with biotech startups for patient-specific medication profiles.
US Sustained Release Coatings Market Revenue (USD Million), 2020-2035
The market revenue chart demonstrates a steady upward trend from 2020 to 2035. In 2020, revenue stood at USD 170.0 million, climbing to USD 276.4 million by 2025 and projected to reach USD 689.7 million by 2035. This robust growth is attributable to pharmaceutical industry advancements, regulatory support for novel drug delivery technologies, and increasing adoption among nutraceutical and generic drug manufacturers. The CAGR of 8.7% highlights both innovation and expanding end-use sectors. The ongoing shift towards continuous manufacturing and sustainability is likely to further accelerate market momentum past 2030, with the final years witnessing sharper revenue increases as new therapeutic categories emerge.
US Sustained Release Coatings Market by Region Share (%), 2025
The pie chart for 2025 reveals the regional distribution of the sustained release coatings market within the US. The South region leads with 32% market share, reflecting the concentration of major pharmaceutical manufacturing hubs. The Midwest follows with 23%, driven by its strong contract manufacturing base. The Northeast, including the pharma corridor, commands a 20% share, while the West accounts for 18% due to its growing biotech scene. The Rest of the US covers the remaining 7%. This regional spread is influenced by R&D investments, proximity to key customers, and state-level incentives for pharmaceutical development.
Recent Developments in US Sustained Release Coatings Market (Last 6 Months)
In April 2024, Evonik Industries launched a new line of EUDRAGIT® polymers optimized for continuous manufacturing of oral solid dosage forms, enabling pharmaceutical clients in the US to produce sustained release drugs with higher efficiency and scalability. This move aims to capture demand from both branded and generic manufacturers shifting towards Industry 4.0 in pharma operations.
In March 2024, Colorcon Inc. announced the expansion of its coating manufacturing facility in Pennsylvania, doubling its production capacity for sustained release coatings. This strategic investment is aimed at meeting the growing contract manufacturing sector's requirements as well as accelerating innovation in customized multi-particulate coating solutions for complex drug delivery.
In February 2024, Catalent introduced an integrated quality management platform for its solid oral dosage business, streamlining regulatory compliance for sustained release coatings. By incorporating real-time monitoring and PAT (Process Analytical Technology) into its processes, Catalent has enhanced transparency for its pharmaceutical clients, facilitating faster regulatory review and improved time-to-market for new coated products.
Press Releases